Literature DB >> 28650098

Disparities in Eurotransplant liver transplantation wait-list outcome between patients with and without model for end-stage liver disease exceptions.

Andreas Umgelter1, Alexander Hapfelmeier2, Wouter Kopp3, Marieke van Rosmalen3, Xavier Rogiers4, Markus Guba5.   

Abstract

The sickest-first principle in donor-liver allocation can be implemented by allocating organs to patients with cirrhosis with the highest Model for End-Stage Liver Disease (MELD) scores. For patients with other risk factors, standard exceptions (SEs) and nonstandard exceptions (NSEs) have been developed. We investigated whether this system of matched MELD scores achieves similar outcomes on the liver transplant waiting list for various diagnostic groups in Eurotransplant (ET) countries with MELD-based individual allocation (Belgium, the Netherlands, and Germany). A retrospective analysis of the ET wait-list outflow from December 2006 until December 2015 was conducted to investigate the relation of the unified MELD-based allocation to the risk of a negative wait-list outcome (death on the waiting list or delisting as too sick) as opposed to a positive wait-list outcome (transplantation or delisting as recovered). A total of 16,926 patients left the waiting list with a positive (11,580) or negative (5346) outcome; 3548 patients had a SE, and 330 had a NSE. A negative outcome was more common among patients without a SE or NSE (34.3%) than among patients with a SE (22.6%) or NSE (18.6%; P < 0.001). Analysis by model-based recursive partitioning detected 5 risk groups with different relations of matched MELD to a negative outcome. In Germany, we found the following: (1) no SE or NSE, SE for biliary sepsis (BS); (2) SE for hepatocellular carcinoma (HCC), hepatopulmonary syndrome (HPS), or portopulmonary hypertension (PPH); and (3) SE for primary sclerosing cholangitis (PSC) or polycystic liver disease (PcLD). In Belgium and the Netherlands, we found the following: (4) SE or NSE, or SE for HPS or PPH; and (5) SE for BS, HCC, PcLD, or PSC. In conclusion, SEs and NSEs do not even out risks across different diagnostic groups. Patients with SEs or NSEs appear advantaged toward patients with cirrhosis without SEs or NSEs. Liver Transplantation 23 1256-1265 2017 AASLD.
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28650098     DOI: 10.1002/lt.24805

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  5 in total

1.  Sex Disparities in Outcome of Patients with Alcohol-Related Liver Cirrhosis within the Eurotransplant Network-A Competing Risk Analysis.

Authors:  Stephan Listabarth; Daniel König; Gabriela Berlakovich; Petra Munda; Peter Ferenci; Dagmar Kollmann; Georg Gyöeri; Thomas Waldhoer; Magdalena Groemer; Arjan van Enckevort; Benjamin Vyssoki
Journal:  J Clin Med       Date:  2022-06-24       Impact factor: 4.964

Review 2.  The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases.

Authors:  Andre Gorgen; Hala Muaddi; Wei Zhang; Ian McGilvray; Steven Gallinger; Gonzalo Sapisochin
Journal:  Can J Gastroenterol Hepatol       Date:  2018-01-10

3.  Milan criteria in the MELD era-is it justifiable to extend the limits for orthotopic liver transplantation?

Authors:  Mehmet Haluk Morgul; Philipp Felgendreff; Andreas Kienlein; Ulrich Gauger; Katrin Semmling; Hans-Michael Hau; Hans-Michael Tautenhahn; Michael Bartels
Journal:  World J Surg Oncol       Date:  2020-07-07       Impact factor: 2.754

4.  Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region.

Authors:  Ben F J Goudsmit; Hein Putter; Maarten E Tushuizen; Jan de Boer; Serge Vogelaar; I P J Alwayn; Bart van Hoek; Andries E Braat
Journal:  Am J Transplant       Date:  2020-08-04       Impact factor: 8.086

5.  Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.

Authors:  Dana Sierks; Ria Schönauer; Anja Friedrich; Elena Hantmann; Jonathan de Fallois; Nikolas Linder; Janett Fischer; Adam Herber; Carsten Bergmann; Thomas Berg; Jan Halbritter
Journal:  JHEP Rep       Date:  2022-09-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.